Global innovator in drug delivery platforms Lexaria
Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) today provided an update on
the ongoing relationship and pursuit of innovation in oral, reduced risk
nicotine consumer products using Lexaria’s patented DehydraTECH(TM) technology.
According to the update, most of the investigation and work within the first
phase of the project underway between Altria Ventures Inc., an indirect wholly
owned subsidiary of Altria Group, Inc (NYSE:MO) and Lexaria’s majority owned
subsidiary Lexaria Nicotine LLC is either complete or significantly underway,
with imminent commencement of one remaining aspect. Results have been positive
to date and support successful completion of this first phase. “The program
between Altria and Lexaria is progressing nicely and is enabling a clearer
understanding of the potential of delivering nicotine through oral forms that
avoid lung absorption,” Lexaria Bioscience and Lexaria Nicotine CEO Chris Bunka
said in the news release. “Lexaria strongly believes that, given the choice,
many of the world’s one billion smokers would elect to experience their
nicotine in a manner that does not rely on either smoking or vaping, and
Lexaria can help enable these alternatives.”
To view the full press releases, visit http://ibn.fm/l3lnA
About Lexaria Bioscience Corp.
Lexaria Bioscience Corp. is a global innovator in drug
delivery platforms. Its patented DehydraTECH(TM) drug delivery technology
changes the way Active Pharmaceutical Ingredients enter the bloodstream,
promoting healthier ingestion methods, lower overall dosing and higher
effectiveness for lipophilic active molecules. DehydraTECH increases
bio-absorption; reduces time of onset; and masks unwanted tastes for orally
administered bioactive molecules including cannabinoids, vitamins,
non-steroidal anti-inflammatory drugs (“NSAIDs”), nicotine and other molecules.
Lexaria has licensed DehydraTECH to multiple companies in the cannabis industry
for use in cannabinoid beverages, edibles and oral products; and to a
world-leading tobacco producer for the development of smokeless, oral-based
nicotine products. Lexaria operates a licensed in-house research laboratory and
holds a robust intellectual property portfolio with 16 patents granted and over
60 patents pending worldwide. For more information, visit the company’s website
at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates
relating to LXRP are available in the company’s newsroom at http://ibn.fm/LXRP
About MissionIRNewsBreaks
MissionIRNewsBreaks provide
a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by
our Team of professional journalists that keep a constant eye on the markets,
these posts are designed to inform you on the latest happenings of our clients
and other publicly traded companies on our radar. From earnings, acquisitions
and agreements to conference attendance and clinical study results, our news
breaks keep you up-to-date with the day’s top movers. MissionIR is primarily
focused on strategic communications. We have executed countless communications
programs to address the needs of companies ranging from start-ups to
established industry leaders, gaining valuable experience and the expertise
necessary to determine the most effective strategy for any given situation.
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
